2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2453

Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Abstract Number: 493

Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Abstract Number: 1823

Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Abstract Number: 443

Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort
Abstract Number: 446

Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Abstract Number: 793

Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Abstract Number: 1572

MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects
Abstract Number: 2866

Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Abstract Number: 1712

Microbial and Metabolic MULTI-Omic Correlations in Systemic Sclerosis Patients
Abstract Number: 1941

Microenvironmental and Systematic Evaluation of the Immunome in Osteoarthritis
Abstract Number: 1835

Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Abstract Number: 954

Microrna-21 Is a Critical Regulator of Autoimmunity through Promoting Effector and Metabolic Function of Pathogenic TH17 Cells
Abstract Number: 2669

Microvascular Flow Assessed By Dynamic Optical Coherence Tomography: First Non-Invasive Quantitative Outcome Measure of Microvascular Disease in Systemic Sclerosis
Abstract Number: 88

Mind Map Use in Rheumatology Education
Abstract Number: 2446

Minimal and Comparable Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Who Continued SB5 or Reference Adalimumab and Who Switched to SB5

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].